Bile acid receptor pathway

Bile acids pathway modulation" is not a single molecular target but refers to the therapeutic targeting of multiple **bile-acid-sensing receptors**—primarily the **Farnesoid X Receptor** (*FXR*), **G protein-coupled bile acid receptor 1** (*TGR5/GPBAR1*), and others such as VDR, PXR, CAR—which are key regulators in metabolic processes. These nuclear and membrane-bound receptors mediate the effects of endogenous and synthetic ligands on lipid/glucose metabolism, immune responses, nutrient absorption, hepatic function, and gut microbiota composition. Pharmacological manipulation through natural or synthetic agonists/antagonists has shown efficacy in treating conditions like cholestatic liver diseases, type 2 diabetes mellitus, non-alcoholic fatty liver disease/nonalcoholic steatohepatitis (*NAFLD/NASH*), inflammatory bowel disease (*IBD*), obesity/metabolic syndrome. The field is rapidly evolving with new drugs targeting these pathways entering clinical use or trials. However, "Bile acids pathway modulation" is a broad process rather than a discrete molecule/receptor; thus it should be mapped to its constituent targets for structured data extraction purposes[1][2][3].

Other names

Bile acid signalingFXR/TGR5 pathwaybile acid receptorsbile acid metabolism modulation

Agonism or antagonism of nuclear and membrane-bound bile acid receptors such as FXR and TGR5[1][2]; Modulation of gene expression involved in lipid/glucose homeostasis, inflammation, fibrosis[4]; Alteration of gut microbiota composition to influence host metabolic pathways[5]